Abstract Since the publication of the first complete microbial genome sequence of Haemophilus influenzae in 1995, more than 200 additional microbial genome sequences have become available in the public domain. Approximately 40% of these represent important human pathogens. Comparative in silico methods, along with large-scale approaches such as transcriptomics and proteomics, are beginning to reveal insights into new virulence genes, pathogen-host interactions, and the molecular basis of host specificity. Sequence data are also starting to accumulate from multiple isolates or strains of a single pathogen, and this type of data has proven to be quite valuable in providing new insights into the genetic variability that is present in a particular species as well as in facilitating correlations between genotype and phenotype. Ultimately, a major goal of genome-enabled infectious disease research is the development of novel diagnostics, therapeutics, and vaccines.
GENOMIC ANALYSIS OF MICROBIAL PATHOGENS
The field of microbial genomics can trace its origins to the 1995 publication of the first genome sequence for a free-living organism, that of the bacterium Haemophilus influenzae (1) . Since then, more than 200 additional microbial genome sequences from organisms distributed throughout the phylogenetic tree have been completed (see http://www.tigr.org/tigr-scripts/CMR2/CMRHomePage.spl). Many of the first projects targeted for genome analysis represented the major bacterial pathogens of humans (see Table 1 ), and these data have provided novel insights into the biology and evolution of each of these species-for example, the identification of novel virulence genes, novel metabolic pathways, and novel cell surface proteins that represent potential new targets for antimicrobial and vaccine development. One of the most consistent observations to emerge from genome studies is that each genome contains a large percentage of predicted open-reading frames (ORFs) (∼20%-40%) that encode proteins of unknown function. A subset of these proteins (∼10%) appears to be unique to each organism and is likely to be involved in species-specific biology. Comparative analysis of microbial genome sequence data has revealed that the microbial genome is a dynamic entity shaped by multiple forces that include gene duplication and gene loss, genome rearrangements, and acquisition of new genes through lateral gene transfer. Each of these mechanisms has been shown to play a key role in the evolution of pathogens and has important implications in epidemiologic studies, spread of antibiotic resistance, and pathogenicity. Often, differences between a pathogen and a nonpathogen cannot be explained solely by gene presence or absence but by subtle single-nucleotide changes. These changes can have disproportionately large consequences. Important virulence genes have been shown to be completely inactivated by such changes.
FRASER RAPPUOLI
Virulence or survival can also be modulated by phase variation in cell-surfaceexpressed genes due to the presence of hypervariable short homopolymeric sequences. These can vary in size during replication, and they can result in frameshifts and inactivation or activation of important virulence genes, as seen in the human pathogens H. influenzae (2) , Helicobacter pylori, Campylobacter jejuni (3), and Neisseria meningitidis (4) .
One example of the type of information that can be obtained from wholegenome analysis comes from a recent study on the Gram-positive bacterium Enterococcus faecalis, which is a natural inhabitant of the mammalian gastrointestinal tract and is commonly found in soil, sewage, water, and food, frequently through fecal contamination (5) . E. faecalis is an opportunistic pathogen that is a major cause of urinary tract infections, bacteremia, and infective endocarditis. The bacterium is intrinsically resistant to many antibiotics and can acquire resistance to 463 other antimicrobial agents, particularly vancomycin, which is used to treat serious infections by drug-resistant Gram-positive pathogens. This resistance has led to the emergence of E. faecalis as a nosocomial pathogen that is refractory to most therapeutic options. More than 25% of the E. faecalis V583 genome consists of mobile and/or exogenously acquired DNA, including seven probable integrated phage regions, 38 insertion elements, multiple conjugative and composite transposons, a putative pathogenicity island, and integrated plasmid genes. This represents one of the highest proportions of mobile elements observed in a bacterial genome. Many of these regions have complex mosaic structures composed of different elements, which may be "hotspots" or "graveyards" for mobile element insertion. This apparent propensity for the incorporation of mobile elements probably contributed to the rapid acquisition and dissemination of drug resistance in the enterococci and suggests that they act as a reservoir for the further dissemination of drug resistance, such as vancomycin resistance via mobile elements and/or conjugative plasmids.
Another recent example of how genomics-based approaches can elucidate the molecular basis of virulence is the description of an isolate of Bacillus cereus (G9241) that possesses the anthrax toxin genes and is capable of causing a severe inhalation-anthrax-like illness (6) . Bacillus anthracis is the etiologic agent of anthrax, an acute, fatal disease among mammals, and is a close relative of B. cereus, an opportunistic pathogen and cause of food poisoning. It has been assumed that one major difference between these species is the presence of plasmids pXO1 and pXO2 in B. anthracis, which encode the lethal toxin complex and the poly-γ -D-glutamic acid capsule, respectively. Although initial phenotypic and 16S rRNA analysis identified this new isolate as B. cereus, the rapid generation and analysis of a high-coverage draft genome sequence revealed the presence of a circular plasmid, named pBCXO1, with 99.6% similarity with the B. anthracis toxin-encoding plasmid, pXO1. Although homologues of the pXO2-encoded capsule genes were not found, a polysaccharide capsule cluster was encoded on a second, previously unidentified plasmid, pBC218. Killing of A/J mice challenged with B. cereus G9241 confirmed the virulence of this strain.
Recently, pathogen genome sequencing efforts have expanded to include multiple representatives of the same species, and this information has proved extremely useful in providing new insights into the genetic variability among strains and in facilitating correlations between genotype and phenotype. Organisms that belong to the same genus can differ in gene content by as much as 25%, as was found when the genome of Escherichia coli K-12 was compared to E. coli O157:H7 (7). Insertion and deletion events appear to account for most of the differences observed. Pathogenicity islands, which are large blocks of self-mobile DNA that carry genes enabling an organism to act as a pathogen, can transfer from one organism and integrate into a new host.
Other pathogens show little variation in chromosomal gene content, as demonstrated by the comparison of the genomes of two isolates of Yersinia pestis (8, 9) , the etiologic agent of plague. Remarkable differences in the chromosome structures, dominated by genome rearrangements, account for most of the variation 464 FRASER RAPPUOLI observed between these two closely related strains. The differences appear to result from multiple inversions of genome segments at insertion sequences. Y. pestis spp. carry most of their virulence determinant on plasmids, which are absent in Y. pseudotuberculosis, the ancestor of Y. pestis. A remarkable number of pseudogenes (degenerated and inactive genes) have been found on the genomes of Y. pestis, an indication of a recent and still evolving genome.
The genomes of three strains of Listeria monocytogenes that have been associated with food-borne illness in the United States were recently subjected to whole-genome comparative analysis, which revealed that the L. monocytogenes genomes are essentially syntenic, with the majority of genomic differences consisting of phage insertions, transposable elements, and single-nucleotide polymorphisms (SNPs) (10) .
Totals of 51, 97, and 69 strain-specific genes were identified in L. monocytogenes strains F2365 (serotype 4b, cheese isolate), F6854 (serotype 1/2a, frankfurter isolate), and H7858 (serotype 4b, meat isolate), respectively (10) . Eightythree genes were restricted to serotype 1/2a and 51 to serotype 4b strains. These strain-and serotype-specific genes probably contribute to observed differences in pathogenicity and to the ability of the organisms to survive and grow in their respective environmental niches. The serotype 1/2a-specific genes include an operon that encodes the rhamnose biosynthetic pathway, which is associated with teichoic acid biosynthesis, as well as operons for five glycosyl transferases and an adeninespecific DNA methyltransferase. Totals of 8603 and 105,050 high-quality SNPs were found on the draft genome sequences of strain H7858 and strain F6854, respectively, when compared with strain F2365.
Although comparative approaches such as those described above can reveal the molecular differences that underlie differences in phenotype among bacterial species or strains, they are not sufficient to uncover the complexities of the interaction between pathogen and host. The availability of other large-scale methods, such as transcriptome and proteome analysis, is allowing investigators to monitor global changes in gene and protein expression in both the pathogen and the host during the infectious process. Another advantage of such methods is that they can also be used to study genes and proteins whose function is unknown.
Recent transcriptome studies of N. meningitidis-a causative agent of septicemia and meningococcal meningitis-provide an excellent example of how transcriptome analysis can be exploited (11, 12) . These studies showed that there were distinct sets of genes that were differentially regulated during two key steps in the meningococcal infection of human cells: the initial interaction with epithelial cells in the respiratory tract and the later interaction with endothelial cells in the blood-brain barrier. These differentially regulated genes-which include those encoding membrane transporters, transcription factors, general metabolic pathway proteins, and a number of hypothetical proteins-are obvious candidates for further studies that in turn could lead to novel approaches to preventing diseases caused by N. meningitidis.
GENOME-BASED DEVELOPMENT OF NOVEL ANTIMICROBIAL AGENTS
Given the increasing rate of appearance of antibiotic-resistant pathogens, there is a great need for the development of novel antibiotics (13) . Traditional approaches to antibiotic development have relied heavily on screening libraries of compounds for the appropriate activity and modification of the structure of existing antibiotics. However, the availability of genome sequence data has catalyzed research on the identification of novel targets for antimicrobial compounds by providing a complete catalog of genes across a wide range of organisms, which can be compared at various levels (14, 15) . The ideal antimicrobial target is (a) essential for viability in the microbial pathogen; (b) absent or significantly different in the human host, a parameter that is much easier to assess now that the human genome sequence is available; and, in the search for targets for broad-spectrum antibiotics, (c) conserved across the appropriate range of organisms.
Genomics has enabled large-scale identification of novel potential targets through in silico comparisons of pathogenic and nonpathogenic strains and mining of existing microbial metabolic databases such as EcoCyc (16) and KEGG (17) . In addition, various experimental approaches are being used to identify genes that are essential for bacterial growth and viability. These approaches include transposon mutagenesis, as has been applied to Mycoplasma genitalium (18) and H. influenzae (19) ; targeted mutagenesis of conserved genes, as has been applied to Streptococcus pneumoniae (20) ; and expression of antisense RNA, as has been applied to Staphylococcus aureus (21) . Results of these collective studies have suggested that between ∼150 and 500 genes may be essential for bacterial cell survival, depending on the particular organism under study. Although this might at first glance appear to be a large number of genes to pursue in follow-up experiments, it represents only ∼10%-15% of the total number of genes in an average genome. One advantage of these kinds of approaches is that they allow an evaluation of the function of all genes in a genome-even those that encode proteins of unknown function. Another approach that has been applied in the search for potential new targets is to use techniques that identify genes that are switched on during infection, such as in vivo expression technology (22) and signature-tagged mutagenesis (23) .
With such approaches, a number of potential new targets have been identified, including aminoacyl tRNA synthetases, polypeptide deformylase, fatty acid biosynthesis, DNA replication, protein secretion, cell division, peptidoglycan biosynthesis, cell signaling, and amino acid biosynthesis proteins (24) (25) (26) . In addition, several proteins of unknown function have also been shown to be essential for cell viability. The next step is to identify small molecular inhibitors of these proteins, often by tapping into the diversity that exists within combinatorial libraries.
The identification of novel targets and antimicrobial compounds will probably not be sufficient to overcome the problem of antibiotic resistance because of the 466 FRASER RAPPUOLI presence of multidrug efflux pumps in prokaryotes that transport a variety of substrates out of the cell (27, 28) . Genomics-based approaches have revealed that multidrug efflux pumps are ubiquitous and most pathogens possess many of these membrane proteins (see http://www.tigr.org/tigr-scripts/CMR2/CMRHomePage.spl). For example, it has been reported that 15%-20% of the genomes of E. coli and Saccharomyces cerevisiae code for transport proteins (30) . Moreover, in certain cases, the genes encoding efflux pumps are present on plasmids that are easily transferred between phylogenetically diverse species (28, 31) . However, the availability of genome sequence data from a large number of important pathogens, along with functional analysis of these proteins, has the potential to greatly increase our understanding of the specificity and regulation of expression of drug efflux pumps and provide additional avenues for discovery of novel pump inhibitors.
GENOME-BASED VACCINE DEVELOPMENT
The official origin of vaccination dates to 1796, when Edward Jenner inoculated James Phipps with a bovine poxvirus to induce an immune response protective against the closely related human pathogen smallpox virus. Almost a century later, Pasteur developed a live attenuated vaccine against rabies and established the following basic steps for vaccine development: isolate, inactivate, and inject the causative organism. The basic principles of Pasteur and Jenner guided vaccine development throughout the twentieth century, and today we enjoy freedom from many once lethal infectious diseases, thanks to those basic principles. All existing vaccines are in fact one of the following types:
1. Killed microorganisms, which contain the causative agent inactivated by chemical or physical treatment. Examples of this type of vaccine are the inactivated polio virus (IPV or Salk) vaccine, the influenza vaccine, the rabies vaccine and the inactivated oral cholera vaccine.
2. Live attenuated microorganisms. These contain the live causative agent, but it has lost the ability to cause disease. Examples are the live attenuated polio vaccine (Sabin), which is being used for the global eradication of polio; the recently licensed intranasal influenza vaccine; the vaccine against measles, mumps, and rubella; and the bacillus Calmette Guerin (BCG) against tuberculosis. 3. Subunit vaccines, which contain purified portions of the causative agents.
Examples are the diphtheria and tetanus toxoid, and the hepatitis B vaccine. 4. A variant of the subunit vaccines are conjugate vaccines, in which a polysaccharide component of the causative agent that is poorly immunogenic on its own is chemically linked to a protein. Examples of conjugate vaccines are the vaccines against type b H. influenzae, the vaccine against pneumococcus, and the vaccine against serogroup C meningococcus.
It is clear from the above description that all vaccines licensed during the twentieth century followed very closely the principle of Pasteur in that their development required growth and inactivation of the microorganism that causes disease. At the turn of the century, ∼20 vaccines were licensed worldwide, and they keep the global population free from diseases that killed millions of people annually just a century ago.
Reverse Vaccinology
Vaccine development entered a new era when the genome of the first bacterium was sequenced in 1995 (1) . Suddenly, the availability of the sequence of all proteins encoded by the pathogen made it possible to predict vaccine components by computer analysis without the need to grow the disease-causing microorganism. For the first time, after more than two centuries, Pasteur's principles of vaccine making were not necessary. The new method, to develop vaccines starting from the genomic information instead of growing the causative organism, was named "reverse vaccinology" (32) . Today no vaccine project is approached without applying the concept of reverse vaccinology.
Reverse vaccinology can be useful for any vaccine project, but there are instances in which the new approach allows development of vaccines that were impossible or very difficult using Pasteur's principles. These can be classified into two major categories:
1. The disease is caused by microorganisms that cannot be grown in the laboratory. Examples of these are hepatitis C virus and Treponema pallidum. In these cases, the vaccines could not be developed for the simple reason that the noncultivable microorganism was not available and therefore could not be killed, attenuated, or used to purify subunit components. 2. The disease is caused by microorganisms that undergo extensive antigenic variation. Examples of these are HIV, meningococcus B and gonococcus. In these cases, Pasteur's approach usually delivered a vaccine that protected against the strain used to vaccinate but could not confer universal protection.
In addition, reverse vaccinology allowed new approaches that were impossible before. For instance, it has become possible to develop vaccines based on epitopes derived from the whole genome. In theory, one could now design a totally synthetic vaccine containing strings of the best epitopes encoded by the microorganism. One could exclude from vaccines those antigens that are predicted to be poorly immunogenic or are potentially cross-reactive with human proteins.
Genomes Used for Vaccine Development
The concept of reverse vaccinology was coined in the attempt to develop a vaccine against serogroup B N. meningitidis, a bacterium that causes ∼50% of the meningococcal cases of sepsis and meningitis. Meningococcal disease used to have a mortality rate of 80% before the introduction of antibiotics, and it still has a mortality rate of 5%-15% despite the sophisticated tools of modern medicine. The disease is caused by an encapsulated Gram-negative bacterium, which, based on the chemical composition of the polysaccharide capsule, belongs to one of five major serogroups (A, B, C, Y, and W135). Vaccination is the only way to control this disease. Polysaccharide vaccines against serogroups A, C, Y, and W135 have been available since 1970. Although effective in adults, these do not work in infants and young children and do not induce immunological memory. A conjugate vaccine, in which the capsular polysaccharide is chemically coupled to a protein carrier, has recently been licensed against meningococcus C. The vaccine works in all age groups, including infants, and induces long-lasting immunological memory. Following mass vaccination, the vaccine wiped out the disease from the United Kingdom within a few months after introduction (33) and is having a similar impact in all countries where the vaccine is being introduced. Conjugate vaccines against serogroups A, C, Y, and W135 are presently in clinical development and are expected to be licensed shortly (34) .
However, a conjugate vaccine is unlikely to be useful for meningoccocus B because the capsular polysaccharide is a polysialic acid, identical in structure to the one present in human glycoproteins such as N-CAM. We are therefore tolerant to this self antigen, and any attempt to bypass tolerance will end up inducing autoimmunity (35) . During the past 40 years, many other approaches to vaccine development against meningococcus B using protein antigens have failed to produce an effective vaccine that works against all strains. In a field where conventional technologies had failed to deliver a vaccine, genomics appeared as a logical and promising resource that could lead to a vaccine. In this perspective, a collaboration was set up in 1997 between Craig Venter at The Institute for Genomic Research (TIGR), the Chiron group in Siena, and Richard Moxon in Oxford to sequence the genome of meningococcus B (36) and use the information to develop a vaccine. Sequencing started in early 1998, and while it was in progress, computer analysis was used to predict surface exposed antigens. Among the 2158 predicted ORFs, ∼600 were selected as possible vaccine candidates in silico; 350 of them were expressed in E. coli and used to immunize mice. Within 18 months, 29 novel antigens able to elicit an antibody response that could kill the bacteria in vitro in the presence of complement were discovered (37) . This property of the antibodies is known to correlate with vaccine efficacy in humans (38) . Sequencing of the genes in a panel of strains representative of the meningococcal population indicated that some of the antigens were conserved and likely to induce immunity against all meningococcal isolates. Two years were then required to prioritize the 29 vaccine candidates and identify the best ones to be tested individually in clinical trials. In 2002 a clinical trial started to evaluate the first genome-derived vaccine in humans (Figure 1) . The trial showed promising immune responses and allowed the design of a second-generation vaccine containing a cocktail of antigens that in preclinical studies was able to cover nearly all meningococcus B isolates. The second-generation vaccine started clinical trials in 2004.
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The meningococcus B project, published in the year 2000 (36) , provided evidence that reverse vaccinology was very powerful in discovering novel antigens and that the conventional approach to vaccine development had become obsolete. This implied that any future vaccine discovery would strongly benefit from taking genomic information into account. The enormous progress in DNA sequencing technologies, pushed by the Human Genome Project, made available most of the genomes of bacterial pathogens within a few years. Soon, reverse vaccinology approaches were described for S. pneumoniae (39) , Group A streptococcus (40) , Group B streptococcus (41) , Porphyromonas gingivalis (42) , and Chlamydia (43) .
In the case of S. pneumoniae, the genomic sequence done by TIGR in 2001 (44) was used by Medimmune to search for secreted proteins using hydrophobic leader sequences (39) . A total of 130 ORFs encoding proteins with secretion motifs or similarity with known virulence factors were identified; 108 of the 130 proteins were cloned, expressed, and used to immunize mice. Six of the proteins were shown to confer protection against disseminated S. pneumoniae infection in this model.
Another example of a bacterium approached with the reverse vaccinology strategy is represented by the periodontal pathogen P. gingivalis, which is implicated in the etiology of chronic adult periodontitis (45) . In this case, the bioinformatic tools were applied to identify 120 novel vaccine candidates (42) . After recombinant expression and purification, the proteins were used to immunize mice and finally tested for protection in the mouse abscess model of infection. Two of the predicted antigens were found to induce a protective immune response.
Chlamydia pneumoniae and C. trachomatis are obligate intracellular pathogens implicated in respiratory and genital infections, respectively (46) . The obligate intracellular growth has made conventional vaccine development almost impossible. Previous attempts focused on OmpA, which, being one of the most abundant proteins, was the only one that could be tested. Again, the genome sequences made all putative antigens available to the reverse vaccinology approach, which has identified many novel protective molecules (47) .
Staphylococcus aureus, following acquisition of resistance to most available antibiotics, has emerged as an important opportunistic pathogen, which infects wounds and causes severe infections. The application of reverse vaccinology to the study of this difficult pathogen has led to the identification of many novel vaccine candidates (48) . The speed and effectiveness of reverse vaccinology were evident during the 2003 outbreak of severe acute respiratory syndrome (SARS). Less than a month after the first observation that a coronavirus was involved in the disease, the genomic sequence was available (49, 50) . Three months later, vaccines had been shown to be able to induce neutralizing antibodies (K. Stadler & R. Rappuoli, unpublished) , and in six months, protection in animal models was achieved (51, 52) . The ability to respond rapidly to emerging infections is another advantage provided by reverse vaccinology. Although the method has been extremely successful in generating innovative vaccines that are protective in animal models, only the results of ongoing clinical trials will tell us the real 
Comparative Genomics and Vaccine Development
The >200 complete sequences of bacterial genomes and the >1600 sequences of viral genomes provide an unprecedented amount of information that allows a more targeted approach to vaccine development and facilitates the discovery of novel targets for antimicrobials. Analysis of single genomes is no longer satisfactory. New, powerful computing platforms make it possible to compare one genome against another in a few seconds and one genome against all known genomes within a few minutes. Analysis of whole genome sequence information is essential in order to make better predictions and identify novel targets with a high degree of certainty.
An example of a genome comparison that was useful in the field of vaccines is the analysis of the differences between the genomes of Mycobacterium bovis strain Bacille Calmette Guerin (BCG) and M. tuberculosis (50) . The analysis showed many genetic differences that may be responsible for the incomplete protection that the BCG vaccine induces against tuberculosis (53) . A solution to the problem of the mycobacterium tuberculosis vaccine may be to add some of the missing genes into the BCG vaccine strain.
In addition to the identification of novel vaccine candidates, genome comparison can be used to select B and T cell epitopes, to enter the emerging field known as computational immunology (54) . Tools to scan genomes for major histocompatibility ligands and predict their affinity permit the design of epitope-based vaccines that contain only selected subsequences. Complex vaccines containing T helper and B cell epitopes alongside cytotoxic T lymphocyte epitopes derived from a variety of pathogens (e.g., five viruses and one bacterium) have already been constructed and tested (55) . These can be synthesized directly after selection from a genome sequence database.
A typical epitope-based vaccine construct contains a single start codon with epitopes inserted consecutively in the construct, with or without intervening spacer amino acids. In vitro studies of these constructs have confirmed that the epitopes are expressed, stimulate protective immune responses, and do not interfere with one another (56) . Another epitope-driven vaccine approach is to mix several plasmids together, each of which contains genes for different proteins or different minigene epitopes (57) .
Although the concept of epitope-driven vaccines for infectious diseases is novel, the concept of epitope-driven vaccines is well accepted in the cancer vaccine field. A number of epitope-driven melanoma vaccines have successfully passed preclinical tests and are either currently in phase I/II clinical trials or awaiting trials soon to be initiated (58, 59) .
Finally, another approach to infectious disease prevention and therapy is based on passive immunization with human monoclonal antibodies (mAb). The origins of this approach date back to 1890, when Behring and Kitasato discovered that immunization with low doses of sterile culture supernatants of tetanus or diphtheria induced sera able to cure (by passive immunization) animals showing the symptoms of disease. During the following century, sera were one of the most important life-saving tools to treat diphtheria, tetanus, anthrax, botulinum, rabies, and viral infections. However, animal sera and human gamma globulins have largely disappeared from the anti-infection tool-box during the past 20 years, mostly because of the toxic reactions (serum sickness) caused by injecting humans with horse sera, and the decreased popularity of blood derivatives. A new technology to efficiently clone human memory B cells from infected or immunized people may transform the field (60) . This technology allowed screening for very-high-affinity human monoclonals against the SARS virus and the isolation of clones that may be therapeutically effective at 0.1-1.0 mg/kg. This would make industrial development possible and provide a realistic solution for the prophylaxis and control of human SARS infection.
Passive antibody therapy has also been exploited to prevent pneumococcal pneumonia using mAbs directed against pneumolysin (PLY), an important virulence factor of S. pneumoniae. In a mouse model of bacteremia, administration of anti-PLY mAbs was associated with significant decrease in lung colonization and lower frequency of bacteremia (61) . Efforts to develop antibody-based therapies can, therefore, be extremely useful in promoting vaccine development.
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